Adaptive Immune Signature in HER2-Positive Breast Cancer in NCCTG (Alliance) N9831 and NeoALTTO Trials

The authors identified a novel 17-gene adaptive immune signature, which was found to be significantly associated with improved recurrence-free survival among patients who received adjuvant trastuzumab but not in patients who received chemotherapy alone.